

Basic information

2021/2616(DEA)

DEA - Delegated acts procedure

Examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products

Supplementing [1999/0134\(COD\)](#)

Subject

3.10.08 Animal health requirements, veterinary legislation and pharmacy

4.20.01 Medicine, diseases

4.20.04 Pharmaceutical products and industry

4.20.05 Health legislation and policy

Procedure completed - delegated act enters into force

Key players

European Parliament	Committee responsible	Rapporteur	Appointed
	ENVI Environment, Public Health and Food Safety	Chair on behalf of committee CANFIN Pascal (Renew)	09/03/2021

Key events

Date	Event	Reference	Summary
24/03/2021	Non-legislative basic document published	C(2021)01603	
24/03/2021	Initial period for examining delegated act 3 month(s)		
07/04/2021	Delegated act not objected by Council		
27/04/2021	Decision by Parliament	T9-0134/2021	
28/04/2021	Committee referral announced in Parliament		

Technical information

Procedure reference	2021/2616(DEA)
Procedure type	DEA - Delegated acts procedure
Procedure subtype	Examination of delegated act
Amendments and repeals	Supplementing 1999/0134(COD)
Legal basis	Rules of Procedure EP 0114-p6
Stage reached in procedure	Procedure completed - delegated act enters into force
Committee dossier	ENVI/9/05567

Documentation gateway

European Parliament

Document type	Committee	Reference	Date	Summary
Recommendation for early non-objection of delegated act		B9-0226/2021	23/04/2021	
Text adopted by Parliament, single reading		T9-0134/2021	27/04/2021	

European Commission

Document type	Reference	Date	Summary
Non-legislative basic document	C(2021)01603	24/03/2021	
Document attached to the procedure	C(2021)4187	08/06/2021	

Additional information

Source	Document	Date
European Commission	EUR-Lex	